Fluorescent Lymphocytes and Smudge Cells Explored in Infectious Mononucleosis
|
By LabMedica International staff writers Posted on 30 Aug 2021 |

Image: The Sysmex DI-60 is an automated, cell-locating image analysis system. It is connected directly to the analyzer track and therefore eliminates the need for manual intervention in the hematology workflow in the imaging cycle (Photo courtesy of Sysmex Corporation)
Infectious mononucleosis (also known as Glandular fever) is an infection most commonly caused by the Epstein-Barr virus (EBV), which is a human herpes virus. Glandular fever is not particularly contagious. It is spread mainly through contact with saliva, such as through kissing, or sharing food and drink utensils.
The mono test is 71% to 90% accurate and may be used as an initial test for diagnosing infectious mononucleosis (IM). However, the test does have a 25% false-negative rate due to the fact that some people infected with EBV do not produce the heterophile antibodies that the mono test is designed to detect. Atypical lymphocytes appear, but the heterophilic agglutination test is negative.
Clinical Laboratorians at the Peking University Third Hospital (Beijing, China) enrolled in a study 62 IM patients, 67 healthy controls, 84 patients with upper respiratory tract virus infection, and 35 patients with malignant lymphoid diseases, to explore the diagnostic value of high fluorescent lymphocytes (HFLC) and smudge cells for infectious mononucleosis (IM). The complete blood counts and leukocyte differential counts were tested, and the smudge cells were manually counted.
Complete blood counts including red blood cells (RBC), hemoglobin (HGB), white blood cells (WBC), and leukocyte differential count, platelet (PLT), and HFLC percentage (HFLC%) were investigated with the Sysmex XN 9000 (Sysmex Corporation, Kobe, Japan). Manual leukocyte classification and smudge cells were counted by Sysmex DI-60. A total of 200 nucleated cells were read on each slide. The number of smudge cells seen per 100 nucleated cells was counted, and the blood smears were observed by two experienced technicians under an optical microscope.
The investigators reported that the value of HFLC% and smudge cells of the IM group were significantly higher than those of healthy controls and disease controls, and the HFLC% value of IM patients was positively correlated with the number of reactive lymphocytes. When the cutoff value of HFLC% was 0.4%, and of IM was high (AUC = 0.995). When the smudge cells >2/100 nucleated cells, the diagnostic value was further enhanced (AUC = 1.000). When the cutoff value of the HFLC% was 1.2%, it effectively distinguished IM patients from upper respiratory tract virus infection patients (AUC = 0.934). When smudge cells >16/100 nucleated cells, it also has high differential diagnosis value (AUC = 0.913). The combination HFLC% and smudge cells for the differential diagnosis can be increased to 0.968.
The authors concluded that HFLC% and smudge cells can be used as effective indicators in the early diagnosis and differential diagnosis of IM. HFLC% assists the diagnosis of IM with the following advantages: first, this indicator has high specificity and sensitivity for the diagnosis of IM, which can effectively avoid missed diagnosed; second, HFLC%, as one of the blood routine indicators, can be obtained directly from the automatic blood analyzer. The study was published on August 17, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Peking University Third Hospital
Sysmex Corporation
The mono test is 71% to 90% accurate and may be used as an initial test for diagnosing infectious mononucleosis (IM). However, the test does have a 25% false-negative rate due to the fact that some people infected with EBV do not produce the heterophile antibodies that the mono test is designed to detect. Atypical lymphocytes appear, but the heterophilic agglutination test is negative.
Clinical Laboratorians at the Peking University Third Hospital (Beijing, China) enrolled in a study 62 IM patients, 67 healthy controls, 84 patients with upper respiratory tract virus infection, and 35 patients with malignant lymphoid diseases, to explore the diagnostic value of high fluorescent lymphocytes (HFLC) and smudge cells for infectious mononucleosis (IM). The complete blood counts and leukocyte differential counts were tested, and the smudge cells were manually counted.
Complete blood counts including red blood cells (RBC), hemoglobin (HGB), white blood cells (WBC), and leukocyte differential count, platelet (PLT), and HFLC percentage (HFLC%) were investigated with the Sysmex XN 9000 (Sysmex Corporation, Kobe, Japan). Manual leukocyte classification and smudge cells were counted by Sysmex DI-60. A total of 200 nucleated cells were read on each slide. The number of smudge cells seen per 100 nucleated cells was counted, and the blood smears were observed by two experienced technicians under an optical microscope.
The investigators reported that the value of HFLC% and smudge cells of the IM group were significantly higher than those of healthy controls and disease controls, and the HFLC% value of IM patients was positively correlated with the number of reactive lymphocytes. When the cutoff value of HFLC% was 0.4%, and of IM was high (AUC = 0.995). When the smudge cells >2/100 nucleated cells, the diagnostic value was further enhanced (AUC = 1.000). When the cutoff value of the HFLC% was 1.2%, it effectively distinguished IM patients from upper respiratory tract virus infection patients (AUC = 0.934). When smudge cells >16/100 nucleated cells, it also has high differential diagnosis value (AUC = 0.913). The combination HFLC% and smudge cells for the differential diagnosis can be increased to 0.968.
The authors concluded that HFLC% and smudge cells can be used as effective indicators in the early diagnosis and differential diagnosis of IM. HFLC% assists the diagnosis of IM with the following advantages: first, this indicator has high specificity and sensitivity for the diagnosis of IM, which can effectively avoid missed diagnosed; second, HFLC%, as one of the blood routine indicators, can be obtained directly from the automatic blood analyzer. The study was published on August 17, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Peking University Third Hospital
Sysmex Corporation
Latest Microbiology News
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







